On December 20, 2017 we reported that the FDA was developing medication guides for gadolinium-based contrast agents (GBCAs). Prior to receiving a GBCA every patient in the outpatient setting, parent and caregiver would be asked to read the new medication guide which would explain the possible risks. On May 16, 2018, the medication guides for GBCAs were approved by the FDA and include the following agents: Gadoterate meglumine (Dotarem, Guerbet) Gadoxetate (Eovist, Bayer HealthCare) Gadobutrol (Gadavist, Bayer) Gadopentetate dimeglumine (Magnevist, Bayer) Gadobenate dimeglumine (MultiHance, Bracco Imaging) Gadodiamide (Omniscan, GE Healthcare) Gadoversetamide (Optimark, Guebert) Gadoteridol (ProHance, Bracco) The following day, on May 17, 2018, the Spine Intervention Society (SIS) issued a patient safety alert about the new medication guides. It should be noted that the FDA does not require that hospital in-patients receive medication guides unless patients or caregivers request them. In addition, "A healthcare professional who determines that it is not in a patient's best interest to receive a medication guide because of significant concerns about its effects may direct that it not be provided to that patient," the FDA wrote. "However, the medication guide should be provided to any patient who requests the information." Please spread the word about the FDA’s new guide. We encourage EVERY patient whether in the outpatient or inpatient setting to request a guide prior to receiving a gadolinium-based MRI or MRA. To read more about this latest update click here: https://www.spineintervention.org/news/401404/FDA-Warns-Gadolinium-based-Contrast-Agents-GBCAs-Retained-in-the-Body-Requires-New-Class-Warnings.htm Please join the growing list of advocates and sign our petition so we can help promote the development of safer alternatives and effective treatments to remove gadolinium from patients affected by it.